Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.

Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.
复制标题

DOI:
10.1021/nl102889y
复制
发表时间:
2010-12-08
期刊:
影响因子:
10.8
通讯作者:
Joshi A
Joshi A
中科院分区:
材料科学1区
文献类型:
--
作者:
Bardhan R;Chen W;Bartels M;Perez-Torres C;Botero MF;McAninch RW;Contreras A;Schiff R;Pautler RG;Halas NJ;Joshi A

文献摘要

参考文献

被引文献

相似文献

基于纳米颗粒的局部递送和外部电磁场调制疗法对乳腺癌等软组织癌症具有非凡的前景;然而,了解纳米颗粒在体内的分布和命运对于临床翻译至关重要。在这里,我们证明,通过同时增强近红外荧光和磁共振成像(MRI),可以在光热治疗纳米复合体中引入多种诊断功能。我们在体内跟踪纳米复合体,检测靶向HER2抗体在72小时内对纳米复合体分布的影响。这种方法提供了关于为特定诊断和治疗功能而设计的复杂纳米颗粒的分布和命运的有价值的详细信息。
Nanoparticle-based therapeutics with local delivery and external electromagnetic field modulation holds extraordinary promise for soft-tissue cancers such as breast cancer; however, knowledge of the distribution and fate of nanoparticles in vivo is crucial for clinical translation. Here we demonstrate that multiple diagnostic capabilities can be introduced in photothermal therapeutic nanocomplexes by simultaneously enhancing both near-infrared fluorescence and magnetic resonance imaging (MRI). We track nanocomplexes in vivo, examining the influence of HER2 antibody targeting on nanocomplex distribution over 72 h. This approach provides valuable, detailed information regarding the distribution and fate of complex nanoparticles designed for specific diagnostic and therapeutic functions.
DOI: 10.2217/17435889.3.5.703
发表时间: 2008-10
期刊: Nanomedicine (London, England)
影响因子: --
作者:
Longmire M;Choyke PL;Kobayashi H
通讯作者: Kobayashi H
DOI: 10.1016/s0002-9394(01)01138-2
发表时间: 2001-10-01
影响因子: 4.2
作者:
Costa, RA;Farah, ME;Cardillo, JA
通讯作者: Cardillo, JA
DOI: 10.1073/pnas.152463399
发表时间: 2002-10-01
影响因子: 11.1
作者:
Åkerman, ME;Chan, WCW;Ruoslahti, E
通讯作者: Ruoslahti, E
DOI: 10.1073/pnas.2232479100
发表时间: 2003-11-11
影响因子: 11.1
作者:
Hirsch, LR;Stafford, RJ;West, JL
通讯作者: West, JL
DOI: 10.1021/nl072209h
发表时间: 2007-12-01
期刊: NANO LETTERS
影响因子: 10.8
作者:
Choi, Mi-Ran;Stanton-Maxey, Katie J.;Clare, Susan E.
通讯作者: Clare, Susan E.